This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Altria (MO) Poised on Solid Pricing, Growth in Low Risk Products
by Zacks Equity Research
Altria (MO) gains from rising popularity of IQOS and oral tobacco offerings. Moreover, pricing power is supporting revenue growth.
Phillip Morris (PM) Poised for Growth on RRPs & Strong Pricing
by Zacks Equity Research
Philip Morris' (PM) strong offerings in the reduced risk products space and solid pricing of combustible products are driving growth.
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
RRPs, Pricing Light Up Tobacco Space Prospects: 3 Stock to Watch
by Vidya Nair
Rising popularity of low risk products, along with solid pricing is a boon for a number of tobacco industry players such as PM, MO and TPB. However, low cigarette sales volumes are a concern for several players.
Altria's (MO) Q4 Earnings Miss Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Altria's (MO) fourth-quarter 2020 results reflect strong pricing in smokeable and oral tobacco product segments. However, escalated costs weigh on the bottom line.
Altria (MO) Q4 Earnings Miss Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of -1.98% and 2.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Church & Dwight (CHD) Queued for Q4 Earnings: What's in Store?
by Zacks Equity Research
Church & Dwight's (CHD) fourth-quarter 2020 performance is likely to have benefited from increased demand for products amid the pandemic. Strained gross margins are likely to have been a concern.
Factors to Know Ahead of Altria's (MO) Q4 Earnings Release
by Zacks Equity Research
Altria's (MO) fourth-quarter 2020 results are likely to reflect gains from pricing as well as strength in the Oral Tobacco Products segment, though cigarette volumes have been soft for a while.
McCormick (MKC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
McCormick's (MKC) fourth-quarter fiscal 2020 performance is likely to reflect strength in the Consumer Business unit due to high demand amid COVID-19, while the Flavors Solution unit has been soft.
Here's How Mondelez (MDLZ) is Placed Ahead of Q4 Earnings
by Zacks Equity Research
Higher demand in developed markets amid COVID-19 is likely to get reflected in Mondelez's (MDLZ) fourth-quarter 2020 performance. However, sluggish performance in some emerging markets is a concern.
Altria (MO) Stock Moves -0.26%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $41.83 in the latest trading session, marking a -0.26% move from the prior day.
Will Altria (MO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria (MO) Gains on Low Risk Tobacco Products & Strong Pricing
by Zacks Equity Research
Altria's (MO) efforts to boost oral tobacco offerings and expansion of IQOS across stores are yielding. Moreover, pricing power is aiding revenue growth.
The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group
Top Stock Reports for Apple, Mastercard & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA), and Sanofi (SNY).
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $41.11 in the latest trading session, marking a +0.05% move from the prior day.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $41.59 in the latest trading session, marking a -0.45% move from the prior day.
Will RRPs Growth Keep Driving Philip Morris (PM) in 2021?
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS, which is boosting revenues in the RRPs category.
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $42.87, marking a +0.75% move from the previous day.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $43, moving -0.23% from the previous trading session.
Altria (MO) Gains on Low-Risk Products Amid Soft Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from the popularity of low-risk tobacco alternatives such as IQOS and on!, as well as prudent pricing strategies.
RRPs Gaining Popularity: 3 Tobacco Stocks to Watch in 2021
by Vidya Nair
Tobacco industry players like PM, MO, and TPB are poised to benefit from rising popularity of low-risk tobacco alternatives. However, low cigarette sales volumes are likely to remain a headwind.
Top Research Reports for Facebook, Verizon & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Sanofi (SNY).
Philip Morris's (PM) IQOS 3 Receives FDA Authorization for Sale
by Zacks Equity Research
FDA approves the sale of Philip Morris's (PM) IQOS devices in the United States. The latest device includes a number of technological advancements compared with its predecessors.
Why Is Altria (MO) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.